Category Archives: Global News Feed

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the third quarter of 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020.

Read the original here:
Supernus to Host Third Quarter 2020 Financial Results Conference Call

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

Read this article:
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

See the rest here:
CLINUVEL to Trial Innovative Drug in Stroke

Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.

Read more:
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Basel, Switzerland, October 28, 2020

Here is the original post:
Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with...

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

More:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

Here is the original post:
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

View original post here:
Theratechnologies Appoints Two New Board Members

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

Continue reading here:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

Link:
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol